Aria uses structure-based drug design to identify molecules able to overcome resistance in therapy. Dr. Harvey Berger, Aria Pharmaceuticals chairman & CEO, offers insight on earnings.
Data is a real-time snapshot *Data is delayed at least 15 minutes Market Data Terms of Service
Global Business and Financial News, Stock Quotes, and Market Data and Analysis
More Comments
ADD COMMENTS
PREVIEW COMMENT